Journal article

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

Anne M Fagan, Chengjie Xiong, Mateusz S Jasielec, Randall J Bateman, Alison M Goate, Tammie LS Benzinger, Bernardino Ghetti, Ralph N Martins, Colin L Masters, Richard Mayeux, John M Ringman, Martin N Rossor, Stephen Salloway, Peter R Schofield, Reisa A Sperling, Daniel Marcus, Nigel J Cairns, Virginia D Buckles, Jack H Ladenson, John C Morris Show all

SCIENCE TRANSLATIONAL MEDICINE | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2014

Abstract

Clinicopathological evidence suggests that the pathology of Alzheimer's disease (AD) begins many years before the appearance of cognitive symptoms. Biomarkers are required to identify affected individuals during this asymptomatic ("preclinical") stage to permit intervention with potential disease-modifying therapies designed to preserve normal brain function. Studies of families with autosomal-dominant AD (ADAD) mutations provide a unique and powerful means to investigate AD biomarker changes during the asymptomatic period. In this biomarker study, we collected cerebrospinal fluid (CSF), plasma, and in vivo amyloid imaging cross-sectional data at baseline in individuals from ADAD families en..

View full abstract

Grants

Awarded by DIAN


Awarded by cooperative agreement grant


Awarded by National Institute for Health Research


Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES


Awarded by NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES


Awarded by NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING


Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE


Awarded by NATIONAL INSTITUTE ON AGING


Funding Acknowledgements

Data collection and sharing for this project was supported by DIAN (U19 AG032438; to R.J.B., T.L.S. B., V.D.B., N.J.C., A.M.F., B.G., A.M.G., D.M.H., M.S.J., D.M., RN.M., C.L.M., R.M., J.C.M., J.M.R., M.N.R., S.S., P.R.S., R.A.S., and C.X.) and a cooperative agreement grant (NCRAD U24 AG21886) funded by the National Institute on Aging (NIA), the DIAN Pharma Consortium [Alzheimer's Immunotherapy Program (Janssen Alzheimer Immunotherapy and Pfizer Inc. Alliance), Biogen Idec Inc., Eisai Inc., Elan Pharmaceuticals Inc., Eli Lilly and Company, En Vivo Pharmaceuticals, Genentech Inc., F. Hoffman-La Roche Ltd., Mithridion Inc., Novartis International AG, Pfizer Inc., and Sanofi-Aventis Groupe] (to R.J.B., T.L.S.B., V.D.B., A.M.F., A.M.G., and C.X.), and in part by R01 EB009352 (to D.M.), P30 NS048056 (to D.M.), P50AG016750 (to J.M.R.), the National Institute for Health Research Queen Square Dementia Biomedical Research Unit (to M.N.R.), and the JO & JR Wicking Trust grants 13026 and 20821 (to P.R.S.). This article has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study presentations/publications.